Company milestones

 Home About Us Company milestones
2018 / 11
     Received Innovation Award (Silver) in 2018「The 15th National Innovation Award - Enterprise Innovation Award」.
2018 / 07
     Received Innovation Award (Silver) in 2018 Taipei Biotech Awards.
2018 / 06
     Completed round C of capital increase by cash.
2018 / 05
     The new drug IOP Injection MPB-1514 from MegaPro Biomedical has received approval from the US FDA to conduct Phase II of clinical trials.
2018 / 04
     The Phase II clinical trial plan for new drug IOP Injection MPB-1514 from MegaPro Biomedical was sent to the US FDA for approval.
2018 / 04
     Completed Phase 1b of clinical trials for IOP Injection MPB-1523 in Taipei Veterans General Hospital.
2018 / 02
     The new drug IOP Injection MPB-1523 from MegaPro Biomedical has received approval from the TFDA to conduct Phase II of clinical trials.
2018 / 01
     The new drug IOP Injection MPB-1523 from MegaPro Biomedical has received approval from the US FDA to conduct Phase II of clinical trials.
2017 / 12
     The new drug IOP Injection MPB-1523 from MegaPro Biomedical has received approval from TFDA to conduct Phase 1b of clinical trials.
2017 / 08
     Received the approval from Hsinchu Science Park Bureau to move into the science park.
2017 / 06
     Completed the final report for Phase I of IOP Injection MPB-1523 clinical trial.
2016 / 12
     Completed Phase I of clinical trials for IOP Injection MPB-1523 in Taipei Veterans General Hospital.
2016 / 12
     Received the Start-up Award in the 13th National Innovation Award.
2016 / 10
     Completed round B of capital increase by cash.
2016 / 03
     Began Phase I of clinical trials for IOP Injection MPB-1514 in Taipei Veterans General Hospital.
2016 / 03
     IOP The IOP Injection received the Fast Track Project subsidy from the A+ Industrial Innovative R&D Program by the Ministry of Economic Affairs.
2016 / 02
    Began Phase I of clinical trials for IOP Injection MPB-1523 in Taipei Veterans General Hospital.
2016 / 02
     Received validation from Ministry of Economics as Biotech and New Pharmaceutical Company.
2016 / 01
      Selected as Index Case by Taiwan Center for Drug Evaluation (CDE).
2015 / 12
     The new drug MPB-1523 that MegaPro Biomedical developing has received approval from TFDA to conduct Phase I of clinical trials.。
2015 / 08
     Process changes to the business industry by adding western medicine wholesale industry, western medicine retail industry, medical equipment wholesale industry, medical equipment retail industry and pharmaceutical testing industry.
2015 / 08
     Shortlisted for the Promising New Enterprise Award in Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award.
2015 / 01
     Complete round A of capital increase by cash.
2015 / 01
     The team spin-off from ITRI.
2014 / 11
    Establishment of the company.